Putting Early Cancer Detection to the Test
 |
|
In this recent Nature Outlook article, Lori Minasian, M.D., deputy director of NCI’s Division of Cancer Prevention (DCP), talks about the goals of the Cancer Screening Research Network’s first clinical trial of multi-cancer detection (MCD) tests, the Vanguard Study.
Read the article.
|
Research in Context: Detecting Cancer
In this NIH Research Matters article, Christos Patriotis, Ph.D., a program officer in DCP, explains how researchers are working to integrate liquid biopsies into other aspects of cancer care such as screening and early detection.
Read the article.
|
Abnormal Results from Prenatal Blood Test Could Point to Cancer in the Mother
Women who are pregnant routinely undergo prenatal blood testing to screen their fetuses for chromosomal disorders such as Down syndrome. In rare cases, this noninvasive prenatal testing (NIPT) results in an abnormal or inconclusive finding that isn’t related to the fetus but rather, to the mother’s DNA. Results of a study of more than 100 women with unusual NIPT findings but a normally developing fetus now show that such findings can have serious implications for the mother. Bernard Parker, M.D., a program officer in DCP’s Community Oncology and Prevention Trials Group, was part of this study, helping mothers who were diagnosed with cancer.
Read the Cancer Currents Blog.
|
Prevention and Screening Have Been Major Contributors to Saving Lives In Five Cancer Types
This publication, led by Katrina Goddard, Ph.D., director of NCI’s Division of Cancer Control and Population Sciences, and DCP Director Philip Castle, Ph.D., M.P.H., describes how improvements in cancer prevention and screening have stopped more deaths from five cancer types combined over the past 45 years than treatment advances.
Read the press release.
|
TMIST Breast Cancer Screening Trial Exceeds Enrollment Goal
The DCP-supported Tomosynthesis Mammographic Imaging Screening Trial (TMIST) surpassed its goal, enrolling 108,508 women to the study, as announced by the ECOG-ACRIN Cancer Research Group, which is leading the trial. TMIST is the first randomized controlled trial aimed at identifying women for whom digital breast tomosynthesis (DBT or 3-D mammography) may be more effective than two-dimensional (2-D) digital mammography in reducing the risk of advanced breast cancer. Having met its enrollment goal, the study will continue with regularly scheduled mammograms and follow-up on all participants through 2027.
Read the press release.
|
JNCI Monograph on Statistical and Practical Considerations in Design and Analysis of Clinical Trials with Patient-Centered Outcomes
DCP’s Cecilia Lee, Dr.P.H., RN, program officer in Community Oncology and Prevention Trials, along with many statisticians and grantees, contributed to this March 2025 issue of JNCI Monographs.
Read the issue.
|
In case you missed it:
Read more DCP Updates.
Follow DCP's LinkedIn page.
See all Meetings and Events on the DCP Website.
Do you forward DCP Updates to others?
Encourage them to subscribe.
|
